share_log

Lyell Immunopharma Analyst Ratings

Benzinga Analyst Ratings ·  Jan 24, 2023 09:04
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/24/2023 34.23% Morgan Stanley $7 → $4 Maintains Equal-Weight
11/14/2022 134.9% Morgan Stanley $15 → $7 Downgrades Overweight → Equal-Weight
11/11/2022 Goldman Sachs Downgrades Buy → Neutral
10/17/2022 302.68% HC Wainwright & Co. → $12 Initiates Coverage On → Buy
05/24/2022 302.68% Goldman Sachs $21 → $12 Maintains Buy
03/31/2022 604.7% Goldman Sachs $31 → $21 Maintains Buy
01/06/2022 571.14% Morgan Stanley $25 → $20 Maintains Overweight
07/12/2021 738.93% Morgan Stanley → $25 Initiates Coverage On → Overweight
07/12/2021 738.93% B of A Securities → $25 Initiates Coverage On → Buy
07/12/2021 638.26% JP Morgan → $22 Initiates Coverage On → Overweight
07/12/2021 906.71% Goldman Sachs → $30 Initiates Coverage On → Buy

What is the target price for Lyell Immunopharma (LYEL)?

There is no price target for Lyell Immunopharma

What is the most recent analyst rating for Lyell Immunopharma (LYEL)?

There is no analyst for Lyell Immunopharma

When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?

There is no next analyst rating for Lyell Immunopharma

Is the Analyst Rating Lyell Immunopharma (LYEL) correct?

There is no next analyst rating for Lyell Immunopharma

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment